Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||HX008 + Irinotecan|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|HX008||HX-008|HX 008|Pucotenlimab||Immune Checkpoint Inhibitor 155 PD-L1/PD-1 antibody 105||HX008 is a monoclonal antibody that binds to PD-1 (PDCD1) andblocks its interaction with PD-L1 (CD274) and PD-L2 (PDCD1LG2), blocking downstream signaling and potentially leading to activation of T-cell-mediated immune response against tumor cells and inhibition of tumor growth (PMID: 32106752).|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 10||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|